FindTrial
Sign In

Chiglitazar

DRUG7 trials

Sponsors

Chipscreen Biosciences, Ltd., Shengjing Hospital, Shanghai Jiao Tong University School of Medicine

Conditions

ChiglitazarHepatic ImpairmentMASH - Metabolic Dysfunction-Associated SteatohepatitisMetforminPolycystic Ovary SyndromeRenal ImpairmentT2DMT2DM (Type 2 Diabetes Mellitus)

Phase 1

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function
CompletedNCT05515458
Chipscreen Biosciences, Ltd.Renal Impairment
Start: 2022-11-20End: 2023-07-19Updated: 2024-05-28
Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function
CompletedNCT05515445
Chipscreen Biosciences, Ltd.Hepatic Impairment
Start: 2022-12-03End: 2023-08-23Updated: 2024-05-28
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
CompletedNCT05681273
Chipscreen Biosciences, Ltd.T2DM
Start: 2023-02-17End: 2023-03-21Updated: 2023-06-15

Phase 2

Chiglitazar/Metformin in Non-obese Women With PCOS
CompletedNCT06125587
Shengjing HospitalChiglitazar, Metformin, Polycystic Ovary Syndrome
Start: 2023-11-15End: 2024-11-20Updated: 2025-01-01
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
RecruitingNCT07303803
Shanghai Jiao Tong University School of MedicineMASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)
Start: 2026-01-01End: 2030-12-01Target: 300Updated: 2026-06-03

Phase 3

Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
CompletedNCT02121717
Chipscreen Biosciences, Ltd.Type 2 Diabetes
Start: 2014-06-30End: 2017-11-30Updated: 2019-10-25
Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
CompletedNCT02173457
Chipscreen Biosciences, Ltd.Type 2 Diabetes
Start: 2014-09-30End: 2017-01-31Updated: 2019-10-25

Related Papers

Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol.
2026-05-18
The effects of chiglitazar and metformin on insulin resistance in women with a normal BMI and polycystic ovary syndrome: a randomized controlled study.
2025-12-02
Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes
Diabetes Metabolic Syndrome and Obesity2023-12-011 citations
Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes
Frontiers in Endocrinology2022-04-259 citations
17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)
Diabetes2019-06-015 citations
18-OR: Efficacy and Safety of Chiglitazar vs. Sitagliptin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Noninferiority Phase 3 Trial (CMAS)
Diabetes2019-06-012 citations